CAL
LYEL icon

Capital Advisors Ltd’s Lyell Immunopharma LYEL Stock Holding History

Capital Advisors Ltd’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8
Closed – – 1512
2024
Q2 		$0 Hold
8
– – ﹤0.01% 1533
2024
Q1 		$0 Hold
8
– – ﹤0.01% 1472
2023
Q4 		$0 Buy
+8
New +$288 ﹤0.01% 1398
2022
Q4 		– Sell
-1
Closed – – 1459
2022
Q3 		$0 Buy
+1
New +$135 ﹤0.01% 1390

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Advisors Ltd's LYEL Position: Q3 2024 in Review

Capital Advisors Ltd sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 8 shares.

Capital Advisors Ltd first reported a position in LYEL in Q3 2022 and held it in 4 quarters. The position peaked at $0 in Q2 2024. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

  • Capital Advisors Ltd reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 8 Lyell Immunopharma shares in Q3 2024.
  • Capital Advisors Ltd first reported a position in Lyell Immunopharma in Q3 2022 and held it in 4 quarters.
  • Capital Advisors Ltd's Lyell Immunopharma position peaked at $0 in Q2 2024.
  • 117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Capital Advisors Ltd's 13F filing for Q3 2024, filed 24 Oct 2024.